Effect of glucose-lowering therapies on heart failure

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Nature Reviews Cardiology

• Publication date

  2018-01-25

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/nrcardio.2017.211PMID 29368701
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effects of Vildagliptin on Ventricular Function in Patients With Type 2 Diabetes Mellitus and Heart Failure: A Randomized Placebo-Controlled Trial.

  2018cited by this paper
• Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs

  2017cited by this paper
• Cardiovascular events and all‐cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: A Bayesian meta‐analysis of survival data

  2017cited by this paper
• Gesamtereignisraten für die Hospitalisierung bei Herzinsuffizienz (HHI) bei Neueinstellung auf SGLT-2-Hemmer im Vergleich zu anderen Antidiabetika – Daten aus dem klinischen Alltag aus Deutschland, Schweden und Norwegen mit mehr als 45.000 Typ 2 Diabetes Patienten (CVD-Real)

  2017cited by this paper
• Differential effects of glucagon-like peptide-1 receptor agonists on heart rate

  2017cited by this paper
• Effect of liraglutide, a glucagon‐like peptide‐1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)—a multicentre, double‐blind, randomised, placebo‐controlled trial

  2017cited by this paper
• Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

  2017cited by this paper
• Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults With Type 2 Diabetes.

  2017cited by this paper
• Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis

  2016cited by this paper
• Risk Related to Pre–Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction

  2016cited by this paper
• Cardiovascular events and all-cause mortality associated with sulfonylureas compared to other antihyperglycaemic drugs: A Bayesian meta-analysis of survival data

  2016cited by this paper
• Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.

  2016cited by this paper
• Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial

  2016cited by this paper
• Pioglitazone after Ischemic Stroke or Transient Ischemic Attack.

  2016cited by this paper
• Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

  2016cited by this paper
• 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

  2016cited by this paper
• Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial.

  2016cited by this paper
• Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

  2016cited by this paper
• SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?

  2016cited by this paper
• The Safety of Dipeptidyl Peptidase 4 Inhibitors and the Risk for Heart Failure.

  2016cited by this paper
• 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

  2016cited by this paper
• Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.

  2016cited by this paper
• Cardiovascular safety of dipeptidyl peptidase-4 inhibitors: recent evidence on heart failure.

  2016cited by this paper
• Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial.

  2015cited by this paper
• Glucagon‐like peptide 1 receptor agonist therapy is more efficacious than insulin glargine for poorly controlled type 2 diabetes: A systematic review and meta‐analysis

  2015cited by this paper
• SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials

  2015cited by this paper
• Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.

  2015cited by this paper
• Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial

  2015cited by this paper
• Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

  2015cited by this paper
• Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial.

  2015cited by this paper
• Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.

  2015cited by this paper
• Association of heart failure severity with risk of diabetes: a Danish nationwide cohort study

  2014cited by this paper
• Angiotensin-neprilysin inhibition versus enalapril in heart failure.

  2014cited by this paper
• The Sodium-Glucose Co-Transporter 2 Inhibitor Empagliflozin Improves Diabetes-Induced Vascular Dysfunction in the Streptozotocin Diabetes Rat Model by Interfering with Oxidative Stress and Glucotoxicity

  2014cited by this paper
• Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial.

  2014cited by this paper
• Heart failure in the diabetic population – pathophysiology, diagnosis and management

  2014cited by this paper
• Effects of glucagon‐like peptide‐1 receptor agonists on cardiovascular risk: a meta‐analysis of randomized clinical trials

  2014cited by this paper
• Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial

  2014cited by this paper
• Diabetes Mellitus, Prediabetes, and Incidence of Subclinical Myocardial Damage

  2014cited by this paper
• Erratum to: Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

  2013cited by this paper
• Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes

  2013cited by this paper
• Comparative Safety and Effectiveness of Metformin in Patients With Diabetes Mellitus and Heart Failure: Systematic Review of Observational Studies Involving 34 000 Patients

  2013cited by this paper
• Circulating Dipeptidyl Peptidase IV Activity Correlates With Cardiac Dysfunction in Human and Experimental Heart Failure

  2013cited by this paper
• Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial.

  2013cited by this paper
• Basal insulin and cardiovascular and other outcomes in dysglycemia.

  2012cited by this paper
• Cardiorenal end points in a trial of aliskiren for type 2 diabetes.

  2012cited by this paper
• Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

  2012cited by this paper
• Role of renal proximal tubule transport in thiazolidinedione-induced volume expansion.

  2012cited by this paper
• Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials

  2012cited by this paper
• Dipeptidyl Peptidase-4 Modulates Left Ventricular Dysfunction in Chronic Heart Failure via Angiogenesis-Dependent and -Independent Actions

  2012cited by this paper
• Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus

  2011cited by this paper
• Metformin use in patients with diabetes mellitus and heart failure: friend or foe?

  2010cited by this paper
• Glucagon-Like Peptide-1 Increases Myocardial Glucose Uptake via p38&agr; MAP Kinase-Mediated, Nitric Oxide-Dependent Mechanisms in Conscious Dogs With Dilated Cardiomyopathy

  2010cited by this paper
• ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY GROUP. EFFECTS OF INTENSIVE GLUCOSE LOWERING IN TYPE 2 DIABETES

  2010cited by this paper
• Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial.

  2010cited by this paper
• Effects of intensive blood-pressure control in type 2 diabetes mellitus.

  2010cited by this paper
• Relationship of hemoglobin A1C and mortality in heart failure patients with diabetes.

  2009cited by this paper
• A randomized trial of therapies for type 2 diabetes and coronary artery disease.

  2009cited by this paper
• Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database

  2009cited by this paper
• Metformin treatment in diabetes and heart failure: when academic equipoise meets clinical reality

  2009cited by this paper
• Glucose control and vascular complications in veterans with type 2 diabetes.

  2009cited by this paper
• Intensive glucose control and macrovascular outcomes in type 2 diabetes

  2009cited by this paper
• The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis

  2009cited by this paper
• Heart failure and diabetes mellitus: epidemiology and management of an alarming association.

  2008cited by this paper
• Effects of Ramipril and Rosiglitazone on Cardiovascular and Renal Outcomes in People With Impaired Glucose Tolerance or Impaired Fasting Glucose

  2008cited by this paper
• Effects of intensive glucose lowering in type 2 diabetes.

  2008cited by this paper
• Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.

  2008cited by this paper
• Renal and Vascular Mechanisms of Thiazolidinedione-Induced Fluid Retention

  2008cited by this paper
• A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure.

  2007cited by this paper
• Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.

  2007cited by this paper
• Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials.

  2007cited by this paper
• Do sulfonylurea drugs increase the risk of cardiac events?

  2006cited by this paper
• Dose–response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study

  2006cited by this paper
• An unexpected inverse relationship between HbA1c levels and mortality in patients with diabetes and advanced systolic heart failure.

  2006cited by this paper
• Predictors of mortality and morbidity in patients with chronic heart failure.

  2006cited by this paper
• Thiazolidinediones, Metformin, and Outcomes in Older Patients With Diabetes and Heart Failure: An Observational Study

  2005cited by this paper
• Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure.

  2005cited by this paper
• Early detection of diabetic cardiomyopathy: usefulness of tissue Doppler imaging

  2005cited by this paper
• Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE).

  2005cited by this paper
• Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus.

  2005cited by this paper
• Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.

  2005cited by this paper
• Improved clinical outcomes associated with metformin in patients with diabetes and heart failure.

  2005cited by this paper
• Thiazolidinediones.

  2004cited by this paper
• Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failure

  2004cited by this paper
• Metformin and lactic acidosis: cause or coincidence? A review of case reports

  2004cited by this paper
• Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications.

  2004cited by this paper
• Recombinant Glucagon-Like Peptide-1 Increases Myocardial Glucose Uptake and Improves Left Ventricular Performance in Conscious Dogs With Pacing-Induced Dilated Cardiomyopathy

  2004cited by this paper
• Heart failure prevalence, incidence, and mortality in the elderly with diabetes.

  2004cited by this paper
• Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure: A Consensus Statement From the American Heart Association and American Diabetes Association

  2003cited by this paper
• Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.

  2003cited by this paper
• Screening for and treating left-ventricular abnormalities in diabetes mellitus: a new way of reducing cardiac deaths.

  2002cited by this paper
• Effects of treatment with sulfonylurea drugs or insulin on ischemia-induced myocardial dysfunction in type 2 diabetes.

  2002cited by this paper
• A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes.

  2001cited by this paper
• The impact of diabetes on left ventricular filling pattern in normotensive and hypertensive adults: the Strong Heart Study.

  2001cited by this paper
• Effect of Type 2 Diabetes Mellitus on Left Ventricular Geometry and Systolic Function in Hypertensive Subjects: Hypertension Genetic Epidemiology Network (HyperGEN) Study

  2001cited by this paper
• Separate and joint effects of systemic hypertension and diabetes mellitus on left ventricular structure and function in American Indians (the Strong Heart Study).

  2001cited by this paper
• Emerging concepts in the management of acute myocardial infarction in patients with diabetes mellitus.

  2000cited by this paper
• Impact of diabetes on cardiac structure and function: the strong heart study.

  2000cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper
• The UK Prospective Diabetes study

  1998cited by this paper

• S2I2N0–3 score predicts short‐ and long‐term mortality and morbidity in HFrEF: a post‐hoc analysis of the GUIDE‐IT trial

  2024cites this paper
• Association between the triglyceride glucose index and length of hospital stay in patients with heart failure and type 2 diabetes in the intensive care unit: a retrospective cohort study

  2024cites this paper
• Nanozyme as a rising star for metabolic disease management

  2024cites this paper
• Special Considerations for Management of Diabetes in Adult Patients with Intellectual and Developmental Disabilities

  2023cites this paper
• Association between serum chloride and in-hospital mortality in congestive heart failure with diabetes: Data from the MIMIC-IV database

  2023cites this paper
• Circulating metabolic signatures of heart failure in precision cardiology

  2023cites this paper
• Association of red cell distribution width with the risk of 3-month readmission in patients with heart failure: A retrospective cohort study

  2023cites this paper
• Glimepiride Use is Associated with Reduced Cardiovascular Mortality in Patients with Type 2 Diabetes and Chronic Heart Failure: A Prospective Cohort Study.

  2022cites this paper
• Benefits of SGLT2 inhibitors in arrhythmias

  2022cites this paper
• Metformin, Macrophage Dysfunction and Atherosclerosis

  2021cites this paper
• Cardioprotective mechanism of SGLT2 inhibitor against myocardial infarction is through reduction of autosis

  2021cites this paper
• Pharmacotherapy of diabetes mellitus in patients with heart failure - a nation-wide analysis of contemporary treatment.

  2021cites this paper
• Diabetes Mellitus

  2021cites this paper
• The role of hyperglycaemia in the development of diabetic cardiomyopathy.

  2021cites this paper
• The effects of antidiabetic agents on heart failure

  2021cites this paper
• Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2021; 165:XX

  2021cites this paper
• The Effects of DPP-4 Inhibitors, GLP-1RAs, and SGLT-2/1 Inhibitors on Heart Failure Outcomes in Diabetic Patients With and Without Heart Failure History: Insights From CVOTs and Drug Mechanism

  2020cites this paper
• Cardiomyopathy in obesity, insulin resistance and diabetes

  2020cites this paper
• Use of sodium–glucose co‐transporter‐2 inhibitors in patients with and without type 2 diabetes: implications for incident and prevalent heart failure

  2020cites this paper
• Highly-improved performance of inverted planar perovskite solar cells by glucose modification

  2020cites this paper
• GLP-1 mediated diuresis and natriuresis are blunted in heart failure and restored by selective afferent renal denervation

  2020cites this paper
• Cost‐effectiveness of empagliflozin in the UK in an EMPA‐REG OUTCOME subgroup with type 2 diabetes and heart failure

  2020cites this paper
• Herzinsuffizienzprotektion bei Patienten mit Diabetes mellitus Typ 2 durch SGLT2-Inhibitoren – Evidenzlage und mögliche Mechanismen

  2020cites this paper
• [Heart failure protection by SGLT2 inhibitors in patients with type 2 diabetes mellitus: evidence and possible mechanisms : A systematic review].

  2020cites this paper
• Diabetes e Insuficiencia Cardíaca

  2020cites this paper
• Cardiovascular Safety of Sodium Glucose Cotransporter 2 Inhibitors as Add-on to Metformin Monotherapy in Patients with Type 2 Diabetes Mellitus

  2020cites this paper
• Treatment of Heart Failure with Preserved Ejection Fraction

  2020cites this paper
• Профилактика развития сахарного диабета типа у пациентов с хронической сердечной недостаточностью

  2020cites this paper
• Dapagliflozin — a breakthrough in the search for drugs to treat HFrEF

  2019cites this paper
• Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction

  2019cites this paper
• Insights on the current status and advancement of diabetes mellitus type 2 and to avert complications: An overview

  2019cites this paper
• Preventing and Treating Heart Failure with Sodium-Glucose Co-Transporter 2 Inhibitors.

  2019cites this paper
• Glucagon Receptor Antagonism Ameliorates Progression of Heart Failure

  2019cites this paper
• Phosphodiesterase 5 Associates With β2 Adrenergic Receptor to Modulate Cardiac Function in Type 2 Diabetic Hearts

  2019cites this paper
• 2018 2 D / 3 D CMR tissue tracking versus CMR tagging in the assessment of spontaneous T 2 DM rhesus monkeys with isolated diastolic dysfunction

  2019cites this paper
• GLP1R agonists: primary cardiovascular prevention and oral administration

  2019cites this paper
• Leveraging Signaling Pathways to Treat Heart Failure With Reduced Ejection Fraction.

  2019cites this paper
• Effects of sodium glucose cotransporter type 2 inhibitors on heart failure

  2019cites this paper
• Are SGLT2 inhibitors joining the mainstream therapy for diabetes type 2?

  2019cites this paper
• Stratifying the effects of SGLT2i

  2019cites this paper
• Current pharmacotherapy options for type 2 diabetes

  2019cites this paper
• TRPV1 Antagonists as Novel Anti-Diabetic Agents: Regulation of Oral Glucose Tolerance and Insulin Secretion Through Reduction of Low-Grade Inflammation?

  2019cites this paper
• Problems Experienced in the Second and Third Months After Discharge From a Heart Failure-Related Hospitalization.

  2018cites this paper
• 2D/3D CMR tissue tracking versus CMR tagging in the assessment of spontaneous T2DM rhesus monkeys with isolated diastolic dysfunction

  2018cites this paper
• Dapagliflozin DECLAREd safe

  2018cites this paper
• Histones and heart failure in diabetes

  2018influential citation
• Cardiovascular Safety of Antihyperglycemic Agents: “Do Good or Do No Harm”

  2018cites this paper
• The Dipeptidyl Peptidase 4 Substrate CXCL12 Has Opposing Cardiac Effects in Young Mice and Aged Diabetic Mice Mediated by Ca2+ Flux and Phosphoinositide 3-Kinase γ

  2018cites this paper
• Хроническая сердечная недостаточность и сахарный диабет: патогенез и возможности лечения

  2018cites this paper
• Treatment of chronic heart failure in the 21st century: A new era of biomedical engineering has come

  2018cites this paper
• World Journal of Diabetes

  year unknowncites this paper